Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Alfred L. Garfall et al.|New England Journal of Medicine|2022Cited by 1.2k
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z. Usmani, Amrita Krishnan, Alfred L. Garfall et al.|The Lancet|2021Cited by 321
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyAjay K. Nooka, Niels W.C.J. van de Donk, Raluca Verona et al.|Cancer|2023Cited by 87
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Christie P.M. Verkleij et al.|Blood Advances|2023Cited by 85
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, María‐Victoria Mateos et al.|Cancer|2023Cited by 66